Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H.

Clin Pharmacol Ther. 2010 Jul;88(1):60-8. doi: 10.1038/clpt.2009.252. Epub 2010 Apr 7.

PMID:
20375998
2.

Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.

Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, Martin E, Kaufman DW, Maison P.

Pediatrics. 2009 Feb;123(2):e297-304. doi: 10.1542/peds.2008-1923. Epub 2009 Jan 19.

PMID:
19153164
3.

Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications.

Papay J, Yuen N, Powell G, Mockenhaupt M, Bogenrieder T.

Pharmacoepidemiol Drug Saf. 2012 Mar;21(3):289-96. doi: 10.1002/pds.2276. Epub 2011 Dec 5.

PMID:
22139991
4.

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.

Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC; EuroSCAR Study Group.

J Am Acad Dermatol. 2008 Jan;58(1):25-32. Epub 2007 Oct 24.

PMID:
17919772
5.

Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany.

Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF.

Arch Dermatol. 1991 Jun;127(6):839-42.

PMID:
2036029
6.

Epidemiologic approaches to the study of toxic epidermal necrolysis.

Kaufman DW.

J Invest Dermatol. 1994 Jun;102(6):31S-33S. Review.

PMID:
8006431
7.

Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database.

Lebrun-Vignes B, Guy C, Jean-Pastor MJ, Gras-Champel V, Zenut M; French Network of Regional Centres of Pharmacovigilance and the French Investigators for Adverse Skin Reactions to Drugs.

Br J Clin Pharmacol. 2017 Sep 30. doi: 10.1111/bcp.13445. [Epub ahead of print]

PMID:
28963996
8.
9.

The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective.

Mockenhaupt M, Kelly JP, Kaufman D, Stern RS; SCAR Study Group.

J Rheumatol. 2003 Oct;30(10):2234-40.

PMID:
14528522
10.

Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.

Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC; SCAR Study Group. Severe Cutaneous Adverse Reactions.

Arch Dermatol. 2002 Aug;138(8):1019-24.

PMID:
12164739
11.

Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know?

Tartarone A, Lerose R.

Ther Drug Monit. 2010 Dec;32(6):669-72. doi: 10.1097/FTD.0b013e3181f2f24f. Review.

PMID:
20844465
12.
13.

Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia.

Kamaliah MD, Zainal D, Mokhtar N, Nazmi N.

Int J Dermatol. 1998 Jul;37(7):520-3.

PMID:
9679693
14.

Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?

Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC.

Arch Dermatol. 2000 Mar;136(3):323-7.

PMID:
10724193
15.

Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC; EuroSCAR Study Group.

AIDS. 2001 Sep 28;15(14):1843-8.

PMID:
11579247
16.

[Case-control surveillance of Stevens-Johnson syndrome and Lyell's syndrome. Presentation of the GISED project].

[No authors listed]

G Ital Dermatol Venereol. 1989 Oct;124(10):435-40. Italian.

PMID:
2635688
17.

Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.

Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J.

Neurology. 2005 Apr 12;64(7):1134-8.

PMID:
15824335
18.

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.

Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M; RegiSCAR study group.

Pharmacogenet Genomics. 2008 Feb;18(2):99-107. doi: 10.1097/FPC.0b013e3282f3ef9c.

PMID:
18192896
19.

Carbamazepine--the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years.

Devi K, George S, Criton S, Suja V, Sridevi PK.

Indian J Dermatol Venereol Leprol. 2005 Sep-Oct;71(5):325-8.

20.

Supplemental Content

Support Center